No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CSL Carlisle Companies
- 367.410
- -1.430-0.39%
Close Apr 18 16:00 ET
- 372.720
- +5.310+1.45%
Post 16:44 ET
17.56BMarket Cap24.20P/E (TTM)
373.445High365.790Low264.58KVolume371.570Open368.840Pre Close97.71MTurnover0.56%Turnover Ratio24.20P/E (Static)47.80MShares403.44052wk High6.21P/B17.40BFloat Cap203.33152wk Low3.20Dividend TTM47.36MShs Float403.440Historical High0.87%Div YieldTTM2.08%Amplitude8.919Historical Low369.301Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
Carlisle Cos Is Maintained at Outperform by Oppenheimer
Carlisle Cos Is Maintained at Outperform by Oppenheimer
Expert Ratings For Carlisle Companies
Carlisle Companies (NYSE:CSL) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table summarizes their recent ra
Investors Heavily Search Carlisle Companies Incorporated (CSL): Here Is What You Need to Know
Express News | Carlisle Companies Inc. : Oppenheimer Raises Target Price to $412 From $405: Oppenheimer Raises Target Price to $412 From $405
Calculating The Intrinsic Value Of Carlisle Companies Incorporated (NYSE:CSL)
Key Insights Carlisle Companies' estimated fair value is US$332 based on 2 Stage Free Cash Flow to Equity Carlisle Companies' US$373 share price indicates it is trading at similar levels as its fair
Comments
The share price has tracked EPS growth, suggesting market sentiment towards the shares remains steady. The stock's recent performance has improved, with a better one-year total shareholder return than the five-year return. Dividends have enhanced the total shareholder return.
Those Who Invested in Carlisle Companies (NYSE:CSL) Five Years Ago Are up 202%CSL anticipates robust annualized double-digit earnings growth over the medium term, driven by strong patient demand for its immunoglobulins franchise. The company has bounced back from the pandemic's impact on its blood plasma collections.
The positive trends in Carlisle Companies' ROCE and its ability to consistently reinvest in itself make it an attractive investment. Investors are expecting more growth in the future. However, it's important to check if these trends will continue.
The stock is seen as overpriced by valuation models, making it less attractive for purchase. With the company's low likelihood of significant earnings growth, its investment appeal is diminished. Profits could be made if share prices meet realistic values.
Carlisle Companies' growth is praised, but future performance remains key. Dividends have boosted total shareholder return, despite short-term performance being below market. Effective business strategy is expected to continue but investors should note identified risks.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg